Senti Biosciences, Inc. (SNTI): Price-to-Revenue Ratio

Symbol and logo of brand Senti Biosciences, Inc. (SNTI)

Unique patents and an AI-driven genetic circuit synthesis system create a formidable technological barrier for competitors of Senti Biosciences, Inc. (SNTI). When monitoring the company's P/S ratio on GURU.Markets, it is evident that 77.30 determines the latest valuation metric. However, risks regarding cellular product toxicity and financial losses remain significant. Meanwhile, strong scientific and technical management, coupled with institutional support, ensure the resilience of clinical programs.

SNTI: Senti Biosciences P/S Multiple 04/28/2023 - 11/13/2026

Metric breakdowns and analytics for Senti Biosciences, Inc. (SNTI)

- current price and projected stock value:
Price Chart sentibio.com|SNTI - Price Target Chart
- stock exchange capitalization data:
Market Value Senti Biosciences Inc|SNTI - Real Price to Acquire Entire Company
- issuer book value statistics:
Accounting Value of a Share Senti Biosciences|SNTI - Book Capitalization|Market Value to Equity Ratio sentibio.com|SNTI - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital Senti Biosciences, Inc.|SNTI - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio sentibio.com|SNTI - Company Aggregate Debts|Debts to Book Value Senti Biosciences Inc|SNTI - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Senti Biosciences|Intermediate Liquidity Ratio sentibio.com
- earnings and valuation multiples information:
SNTI - Net Profit|Expected Net Income Senti Biosciences, Inc.|SNTI - P/E Multiple|Projected Price to Earnings Ratio sentibio.com|SNTI - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Senti Biosciences Inc|SNTI - Operating profit EBITDA|Net earnings per share (EPS TTM) Senti Biosciences|SNTI - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months sentibio.com|SNTI - Net earnings per share growth this year|Expected net earnings per share growth next year Senti Biosciences, Inc.
- issuer revenue and sales details:
SNTI - Company Revenue|Company Future Sales sentibio.com|SNTI - P/S Multiple|Market Cap to Future Revenue Ratio Senti Biosciences Inc
General company analysis:SNTI - Senti Bio
Mass-produced product of Senti Bio

An investor assesses the margin of safety for Senti Biosciences, Inc. (SNTI) by evaluating the value of each dollar of revenue relative to market capitalization. For Senti Biosciences, Inc. (SNTI), this balance depends directly on the success of clinical trials for gene circuits in oncology therapy. By analyzing the fundamental P/S ratio, one can determine the extent to which the market overvalues current sales relative to future technological breakthroughs. This asset represents a high-risk venture instrument with potential for exponential growth.

Who Senti Biosciences, Inc. competes with

Price-to-Revenue Ratio LEGN (legendbiotech.com)|Price-to-Revenue Ratio Sana Biotechnology, Inc. SANA|Autolus Therapeutics PLC - Price-to-Revenue Ratio|ALLO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RNAC (Selecta Biosciences Inc.)|CLLS: P/S Multiple|Price-to-Revenue Multiple cariboubio.com CRBU|TIL (Instil Bio) - P/S Multiple|Price to Sales Genenta GNTA|Price-to-Revenue Ratio Century Therapeutics (IPSC)|jaspertherapeutics.com - Market Cap to Revenue Ratio|P/S Multiple ADAP (Adaptimmune Therapeutics)|CERo Therapeutics Holdings, Inc. (CERO) - Price to Sales|TCRT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACHL (Achilles Therapeutics)|CRGX (Cargo Therapeutics) - Market Cap to Revenue|PSTX: Market Cap to Sales Volume|TSVT (2seventy bio, Inc.) - P/S Multiple|GRCL: Market Capitalization-to-Revenue Ratio